Global Biosimilars Market 2017-2019 & 2024: Total of 492 Products in Development Featuring Amgen, Biocon, Celltrion, Dr. Reddy's Laboratories, Pfizer, Samsung Bioepis & Sandoz

News provided by

Jan 22, 2019, 06:45 ET

DUBLIN, Jan. 22, 2019 /PRNewswire/ --

The "Global Biosimilars Market - Increasingly Lucrative Market Fueled by Constrained Payer Environment and Patent Expiries for Best-Selling Biologics" report has been added to ResearchAndMarkets.com's offering.

The Global Biosimilar market by product is projected to grow at a compound annual growth rate (CAGR) of 45.22%

In Europe, the uptake of biosimilars has been heterogeneous across countries due to existing differences in biosimilar policies. However, the biosimilars market is poised to witness strong growth, as the safety of biosimilars has been established and incentives are increasing. Recent incentives such as gain sharing has been a driver for improving biosimilar uptake across multiple European countries.

The US biosimilar market has been hindered by a lack of market access due to legal issues, contracting dynamics, regulatory uncertainties, and lack of prescriber awareness and incentives. However, the recent changes in reimbursement policies can improve biosimilar adoption. Rebate agreements between pharmaceutical companies and pharmacy benefit managers has been a key barrier for biosimilar uptake.

However, the Trump administration has proposed to remove rebates, which could induce market growth in US.

The Japanese biosimilar market growth has been sluggish. However, the market is set to grow, driven by the government's agenda to cut healthcare expenditure. Foreign companies that collaborate with local companies will be best positioned to leverage this opportunity.

Scope

How does the global biosimilar pipeline look like in 2018?
What is the distribution of pipeline biosimilars by stage of development?
Which are the therapy areas set to benefit the most from biosimilar drugs in development?
Which biosimilars are commonly targeted in the pipeline?
How many companies are currently involved in biosimilar drug development? Which are the most active in the pipeline?
What is the size of the global biosimilar market?
How much revenue will promising biosimilar drugs in the market, and in development, record to 2024?
What are the key factors driving growth in the global biosimilars market?
What are the factors restraining the growth of global biosimilar market?
How does legislation regarding biosimilar interchangeability differ among key geographical markets?
How will legal or political changes in the landscape affect the biosimilar market?
What are the key differences in biosimilar regulatory pathways between US, Europe, Japan, South Korea, China, Brazil, and India?
What are the regulatory evidence requirements in each country?

Reasons to buy

Develop an overview of the current biosimilar landscape in key markets
Learn how regulatory or legal changes will affect the market
Identify market prospects

Key Topics Covered:

1 Executive Summary

2 Introduction
2.1 Defining Biosimilars
2.2 Comparative Analysis: Biosimilars vs Generics
2.3 Biobetters
2.4 Why Biosimilars? SWOT Analysis

3 Key Drivers
3.1 Constrained Payer Environment
3.2 Cost-effectiveness
3.3 Patent expiration

4 Key Barriers
4.1 Development complexities and cost
4.2 Strategies from originators
4.3 Interchangeability and substitution concerns

5 Biosimilars In Mature Markets
5.1 Biosimilar Approval Pathways Across Key Mature Markets
5.2 Biosimilars in EU
5.2.1 Developments in the EU Biosimilar Landscape: Gainsharing
5.3 Biosimilars in the US
5.3.1 Developments in the US Biosimilar Landscape: Reimbursement
5.3.2 Developments in the US Biosimilar Landscape: Rebate
5.4 Biosimilars in Japan

6 Biosimilars In Emerging Market
6.1 Biosimilar Approval Pathways Across Key Emerging Markets
6.2 Biosimilars in South Korea
6.3 Biosimilars in China
6.3.1 Developments in the Chinese Biosimilar Landscape: Reforms
6.3.2 Developments in the Chinese Biosimilar Landscape: Investments
6.4 Biosimilars in Brazil
6.5 Biosimilars in India
6.6 Strategies for Biosimilars Manufacturers in Emerging Markets

7 Global Biosimilar Pipeline Analysis
7.1 Global Biosimilar Pipeline by Stage of Development
7.2 Global Biosimilar Pipeline by Therapy Area
7.3 Global Biosimilar Pipeline by Indication: Top 10 targeted indications
7.4 Global Biosimilar Pipeline by Molecule: Top 10 targeted biosimilars
7.5 Most Active Manufacturers in the Global Biosimilar Pipeline: Product Volume by Stage of Development
7.6 Most Active Manufacturers in the Global Biosimilar Pipeline: Product Volume by Molecule
7.7 Most Active Manufacturers in the Global Biosimilar Late Stage Pipeline

8 Global Biosimilar Market And Product Sales Forecast
8.1 Global Rituximab Biosimilar Market Forecast 2017 - 2024
8.2 Rituximab Biosimilar Market: ABP 798 Global Sales Forecast 2017 - 2024
8.3 Global Infliximab Biosimilar Market Forecast 2017 - 2024
8.4 Infliximab Biosimilar Market: Inflectra Global Sales Forecast 2017 - 2024
8.5 Global Trastuzumab Biosimilar Market Forecast 2017 - 2024
8.6 Trastuzumab Biosimilar Market: Kanjinti Global Sales Forecast 2017 - 2024
8.7 Global Bevacizumab Biosimilar Market Forecast 2017 - 2024
8.8 Bevacizumab Biosimilar Market: Mvasi Global Sales Forecast 2017 - 2024
8.9 Global Adalimumab Biosimilar Market Forecast 2017 - 2024
8.10 Adalimumab Biosimilar Market: Global Imraldi Sales Forecast 2017 - 2024
8.11 Insulin Glargine Biosimilar Market: Basaglar Global Sales Forecast 2017 - 2024
8.12 Etanercept Biosimilar Market: Benepali Global Sales Forecast 2017 - 2024

9 Strategic Alliances
9.1 Global Biosimilar Partnership Deals by Region and Value
9.2 Global Biosimilars Partnership Deals by Year
9.3 Global Biosimilar Licensing Deals by Region and Value
9.4 Global Biosimilar Licensing Deals by Year
9.5 Top 10 Targeted Biosimilars in Strategic Alliances
9.6 Most Active Companies in Strategic Alliances

10 Company Profile
10.1 Sandoz
10.2 Pfizer
10.3 Celltrion
10.4 Samsung Bioepis
10.5 Amgen
10.6 Biocon
10.7 Dr. Reddy's Laboratories

11 Bibliography

For more information about this report visit https://www.researchandmarkets.com/research/46gpg7/global?w=5

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets